These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7945169)

  • 1. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
    Fleckenstein-Grün G; Fleckenstein A
    Ann Med; 1991; 23(5):589-99. PubMed ID: 1756029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
    Fleckenstein-Grün G; Frey M; Thimm F; Luley C; Czirfusz A; Fleckenstein A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S1-9. PubMed ID: 1725909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats.
    Fleckenstein-Grün G; Thimm F; Frey M; Matyas S
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):207-13. PubMed ID: 7475044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Hofgärtner W; Fleckenstein A
    Drugs; 1992; 44 Suppl 1():23-30. PubMed ID: 1283581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excessive mural calcium overload--a predominant causal factor in the development of stenosing coronary plaques in humans.
    Fleckenstein A; Frey M; Thimm F; Fleckenstein-Grün G
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1005-13. PubMed ID: 2076386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Fortschr Med; 1984 Jul; 102(27-28):713-7. PubMed ID: 6479813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.
    Fleckenstein A; Frey M; Zorn J; Fleckenstein-Grün G
    Am J Cardiol; 1985 Dec; 56(16):3H-14H. PubMed ID: 2416214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Misinterpretation of coronary cholesterol atheromata in cholesterol-fed rabbits as suitable model for conventional human coronary plaques.
    Thimm F; Frey M; Fleckenstein-Grün G
    Adv Exp Med Biol; 1994; 361():417-24. PubMed ID: 7597965
    [No Abstract]   [Full Text] [Related]  

  • 13. Experimental antiarteriosclerotic effects of calcium antagonists.
    Fleckenstein A; Fleckenstein-Grün G; Frey M; Thimm F
    J Clin Pharmacol; 1990 Feb; 30(2):151-4. PubMed ID: 2312766
    [No Abstract]   [Full Text] [Related]  

  • 14. [Atheroma and calcium antagonists].
    Lechat P; Hadjiisky P
    Therapie; 1993; 48 Spec No():665-70. PubMed ID: 8091352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of two calcium channel blockers--nifedipine and diltiazem--on atherogenesis in hypercholesterolemic hamster.
    Raicu M; Pojoga L; Simionescu N; Simionescu M
    J Submicrosc Cytol Pathol; 1996 Apr; 28(2):265-75. PubMed ID: 8964051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on anti-atherosclerotic therapy.
    Bernini F; Paoletti R
    Eur J Epidemiol; 1992 May; 8 Suppl 1():104-6. PubMed ID: 1505646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular injury: mechanisms and manifestations.
    Nayler WG
    Am J Med; 1991 Apr; 90(4B):8S-13S. PubMed ID: 1826808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can the progression of coronary heart disease be modified by calcium antagonists?].
    Schneider W; Roebruck P; Kober G; Alle M; Cieslinski G; Mildenberger D; Satter P; Kaltenbach M
    Z Kardiol; 1989; 78 Suppl 5():112-20. PubMed ID: 2698562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of nifedipine on experimental arteriosclerosis.
    Knorr AM; Kazda S
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1027-31. PubMed ID: 2076389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.